Altre lingue Tourmaline Bio, Inc.

Azioni

TRML

US89157D1054

Tempo reale stimato Cboe BZX Altri mercati azionari 20:19:18 26/04/2024			Variaz. 5gg	Var. 1 gen.
15,85 ^USD	-0,94%		+2,85%	-39,30%

21/03	Wall Street si appresta ad aprire in rialzo dopo che la Fed ha mantenuto fermi i tassi di interesse; le richieste iniziali di disoccupazione sono più basse del previsto	MT
21/03	I futures statunitensi sono in rialzo dopo la decisione della Fed di mantenere i tassi di interesse invariati	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Certain Common Stock of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected	21/03
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady	21/03
Top Premarket Decliners	21/03
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027	19/03
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	19/03
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024	19/03
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing	31/01
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	29/01
Tourmaline Bio Prices $150 Million Common Stock Offering	25/01
Tourmaline Bio Announces Pricing of Public Offering of Common Stock	25/01
Tourmaline Bio Announces Proposed Public Offering of Common Stock	24/01
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)	08/01
Tourmaline Bio, Inc.(NasdaqGS:TRML) added to NASDAQ Biotechnology Index	18/12
Tourmaline Bio Joins Nasdaq Biotechnology Index	15/12
Tourmaline Bio added to the NASDAQ Biotechnology Index	15/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Tourmaline Bio, Inc.

Azioni

TRML

US89157D1054

Altre lingue

Filtri